On Wednesday, H.C. Wainwright reaffirmed its Buy rating and $9.00 price target for MiNK Therapeutics (NASDAQ:INKT) following the announcement of a research collaboration between MiNK and Autonomous Therapeutics. The partnership is focused on developing new treatments for metastatic tumors by combining Autonomous' precision encrypted RNA (encRNA) technology with MiNK's allogeneic invariant natural killer T (iNKT) cell therapies.
The collaboration will leverage MiNK's MiNK-215 and agenT-797 therapies. MiNK-215 has shown promise in preclinical models, effectively targeting tumor cells and immune-suppressive cells, as well as boosting the presence of proinflammatory cytotoxic T cells. AgenT-797 has displayed potential in a Phase 1 trial, including disease stabilization across several solid tumors and a response in chemotherapy and anti-PD-1 refractory gastric cancer, as reported in the 2024 issue of Oncogene by Carneiro et al.
Autonomous Therapeutics brings to the table its encRNA technology, which includes over 10 candidates, such as the next-generation immunotherapy AT313. This preclinical encRNA candidate is designed for precision targeting in solid tumors, activating therapeutic protein translation only within cancer cells, which could significantly reduce the toxicities seen with traditional cancer treatments.
The companies aim to test these technologies in advanced metastatic solid tumor models and have plans to initiate a Phase 1 clinical trial for patients with treatment-refractory metastatic solid tumors, including microsatellite stable colorectal cancer (MSS-CRC). The partnership is seen as a strategic move for MiNK to potentially enhance its treatment portfolio by integrating Autonomous' technology platform and exploring combination therapies with MiNK-215 and agenT-797.
In other recent news, MiNK Therapeutics has been facing potential delisting from the Nasdaq Stock Market due to non-compliance with market value requirements. The biopharmaceutical company has been granted a 180-day period to regain compliance, with the option to appeal before a Nasdaq Hearings Panel if necessary. This comes after the company failed to meet the minimum bid price requirement, receiving a formal notification from Nasdaq of its non-compliance. As part of its response, MiNK Therapeutics plans to request a hearing to appeal the process.
In terms of recent developments, MiNK Therapeutics has reported progress in its primary cell therapy programs, AgenT-797 and MiNK-215. AgenT-797 is currently in a Phase II trial for gastric cancer and ARDS, with plans for a Phase I trial for GvHD. MiNK-215, which targets solid tumors, is expected to file an IND in 2025. The company has emphasized its financial strategy, engaging in non-dilutive funding and strategic partnerships.
However, despite ending the second quarter of 2024 with a cash balance of $9.3 million and a decrease in operational cash burn compared to the previous quarter, MiNK Therapeutics reported a net loss of $2.7 million for Q2 2024.
InvestingPro Insights
As MiNK Therapeutics (NASDAQ:INKT) embarks on this promising collaboration with Autonomous Therapeutics, investors might benefit from a closer look at the company's financial health and market performance. According to InvestingPro data, MiNK Therapeutics has a market capitalization of $28.08 million USD, reflecting its current position as a small-cap biotech company.
InvestingPro Tips highlight that MiNK holds more cash than debt on its balance sheet, which could provide financial flexibility as it pursues this new research collaboration. This is particularly important given that the company is quickly burning through cash, a common characteristic of biotech firms investing heavily in R&D.
The stock's recent performance has been challenging, with InvestingPro data showing a one-year price total return of -43.5% as of the latest available data. This decline is reflected in the stock's current price, which stands at 35.68% of its 52-week high. However, an InvestingPro Tip suggests that the stock's RSI indicates it may be in oversold territory, potentially signaling a buying opportunity for risk-tolerant investors aligned with H.C. Wainwright's bullish outlook.
It's worth noting that MiNK Therapeutics is not currently profitable, with a negative P/E ratio and operating income. This is not uncommon for early-stage biotech companies focused on research and development. Investors considering INKT should be aware that analysts do not anticipate the company will be profitable this year, according to another InvestingPro Tip.
For those interested in a deeper analysis, InvestingPro offers 8 additional tips for MiNK Therapeutics, providing a more comprehensive view of the company's prospects and challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.